Thakur Raman, Kaur Sumanpreet
Department of Medical Laboratory Sciences, Lovely Professional University, Punjab, 144411, India.
Department of Medical Laboratory Sciences, Lovely Professional University, Punjab, 144411, India.
Microb Pathog. 2025 Jul;204:107580. doi: 10.1016/j.micpath.2025.107580. Epub 2025 Apr 12.
Probiotics are effective in the treatment of diarrheal disease which is the second leading cause of death in children below the age of five years via the production of antimicrobial peptides and lactic acid. These live bacteria are known to benefit the host by modulating their gut microbiome and competitively excluding pathogens from the gut. As probiotics are live microbial cells, their safety evaluation is a concern that shifts the focus from the usage of live cells to parabiotics and postbiotics. In recent years attempts have been made to study the efficacy of postbiotics and parabiotics against enteric pathogens. Enteric pathogens are the major cause of diarrhea resulting in watery stools and electrolyte imbalance. Among various gastrointestinal illnesses, 30 % are caused by bacteria. These gastrointestinal infections in adults have usually mild to moderate symptoms that disappear spontaneously but, in some cases, they can cause chronic diseases such as typhoid, irritable bowel syndrome, ulcerative colitis and bacteremia. The extensive use of antibiotics for the treatment of bacterial-infection-induced diarrhea has led to the emergence of drug resistance among these enteric pathogens. Drug resistance poses a major threat in the treatment of various other diseases as well. Further, the use of antibiotics is known to disrupt the homeostasis of the gut by killing the normal gut flora thereby worsening the situation. Therefore, the urgent need for new interventions to combat these enteric pathogens along with restoration of gut barrier. Lactobacillus-derived parabiotics and postbiotics have emerged as promising approaches for managing and treating diarrheal diseases. Therefore, our research is focused on studying the efficacy and underlying mechanisms of Lactobacillus spp.-derived postbiotics and parabiotics against enteric pathogens. Understanding these mechanisms helps in combatting diarrhea associated with enteric pathogens and results in reducing the morbidity and mortality rates associated with infectious diarrhea and its complications.
益生菌通过产生抗菌肽和乳酸,对五岁以下儿童腹泻病(这是该年龄段儿童死亡的第二大主要原因)的治疗有效。已知这些活细菌通过调节肠道微生物群并竞争性地将病原体排除在肠道之外,从而使宿主受益。由于益生菌是活的微生物细胞,其安全性评估是一个令人担忧的问题,这使得人们的关注点从活细胞的使用转向了副益生菌和后生元。近年来,人们已尝试研究副益生菌和后生元对肠道病原体的功效。肠道病原体是导致腹泻、水样便和电解质失衡的主要原因。在各种胃肠道疾病中,30%是由细菌引起的。成年人的这些胃肠道感染通常症状较轻至中度,会自行消失,但在某些情况下,它们可能会导致慢性疾病,如伤寒、肠易激综合征、溃疡性结肠炎和菌血症。广泛使用抗生素治疗细菌感染引起的腹泻已导致这些肠道病原体产生耐药性。耐药性在治疗各种其他疾病时也构成了重大威胁。此外,已知使用抗生素会通过杀死正常肠道菌群破坏肠道的稳态,从而使情况恶化。因此,迫切需要新的干预措施来对抗这些肠道病原体,并恢复肠道屏障。源自乳酸杆菌的副益生菌和后生元已成为管理和治疗腹泻病的有前景的方法。因此,我们的研究重点是研究源自乳酸杆菌属的后生元和副益生菌对肠道病原体的功效及其潜在机制。了解这些机制有助于对抗与肠道病原体相关的腹泻,并降低与感染性腹泻及其并发症相关的发病率和死亡率。